Issue 6, 2012

Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome

Abstract

Inhibition of the proteasome by covalent inhibitors is a clinically proven anti-cancer therapy. We report here that dipeptides with a P3 neopentyl Asn residue are potent, reversible, non-covalent inhibitors selective for the chymotryptic activity of the 20S proteasome in vitro and in cells. The X-ray structure of compound 20 in complex with yeast 20S reveals the importance of hydrophobic bonding interactions of the neopentyl group within the S3 binding pocket of the 20S β5 sub-unit. Four compounds show comparable potencies to boronic acid inhibitors in a panel of assays.

Graphical abstract: Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome

Supplementary files

Article information

Article type
Concise Article
Submitted
29 Feb 2012
Accepted
16 Apr 2012
First published
19 Apr 2012

Med. Chem. Commun., 2012,3, 710-719

Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome

C. Blackburn, C. Barrett, J. L. Blank, F. J. Bruzzese, N. Bump, L. R. Dick, P. Fleming, K. Garcia, P. Hales, M. Jones, J. X. Liu, M. Nagayoshi, D. S. Sappal, M. D. Sintchak, C. Tsu, C. Xia, X. Zhou and K. M. Gigstad, Med. Chem. Commun., 2012, 3, 710 DOI: 10.1039/C2MD20060K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements